Ph-positive acute lymphoblastic leukemia
Conditions
Interventions
Understand and voluntarily sign an informed consent form:Olverembatinib with vindesine and prednisolone
Sponsors
The First Afflilated Hospital, Zhejiang University School of Medicine,
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia; 2. Aged >= 18 years; 3. Healthy liver and kidney function (creatinine <= 1.5 * ULN, BUN <= 1.5 * ULN, ALT <= 3 * ULN, AST <= 3 * ULN, Total bilirubin <= 3 * ULN); 4. Understand and comply with all test protocol requirements; 5. Accept oral medicine,Understand and voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. CML-BP; 2. Can not come back for eximination on time;Can not understand and voluntarily sign an informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete molecular remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response Rate (CR+CRi);Overall survival;Minimal Residul disease;Major Molecualr remission; | — |
Countries
China
Contacts
Public ContactJin Jie
The First Afflilated Hospital, Zhejiang University School of Medicine
Outcome results
None listed